{"id":"W1996135170","doi":"10.5489/cuaj.10160","title":"Emerging novel therapies in the treatment of castrate-resistant prostate cancer","year":2011,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Denosumab; Prostate cancer; Docetaxel; Hormonal therapy; Ipilimumab; Oncology; Internal medicine; Combination therapy; Nivolumab; Dasatinib; Clinical trial; Abiraterone; Cancer; Pharmacology; Immunotherapy; Tyrosine kinase; Receptor; Osteoporosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00135354,0.0004251972,0.000853179,0.001059214,0.0003376469,0.001163655,0.0007167315,0.00076714,0.003505642],"category_scores_gemma":[0.0005960248,0.0001599411,0.0004815671,0.0008719919,0.0006820438,0.001026491,0.0005213539,0.001984275,0.0009036069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009559304,"about_ca_system_score_gemma":0.001293508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001255805,"about_ca_topic_score_gemma":0.008252297,"domain_scores_codex":[0.9996179,0.000117239,0.00003435171,0.0000301679,0.000151472,0.00004886339],"domain_scores_gemma":[0.9996582,0.0001237319,0.00005856925,0.000009352857,0.00009577435,0.00005437597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003719517,0.0003843236,0.0008871071,0.005519363,0.00008578737,0.001342744,0.000207391,0.0007780855,0.007337878,0.008717357,0.01569259,0.9586754],"study_design_scores_gemma":[0.0005354768,0.002130208,0.005361401,0.00292019,0.0002587644,0.005186178,0.000491083,0.00120818,0.003590895,0.01155647,0.9667109,0.00005035041],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002669221,0.9867066,0.0008636969,0.004125697,0.000613848,0.00002908979,0.00002759305,0.0000219288,0.004942312],"genre_scores_gemma":[0.01462178,0.9772184,0.003190373,0.001697949,0.001094891,0.00003197552,0.00006779459,0.000005302693,0.002071562],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003505642,"threshold_uncertainty_score":0.01172757,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05182196921740727,"score_gpt":0.2997207232699185,"score_spread":0.2478987540525112,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}